Among the recent advances in the molecular targeted therapy of cancer, the applications focused on EGFR are currently the most promising and the most advanced at clinical level (Arteaga, 2001; Baselga, 2001; Ciardiello and Tortora, 2001; Yarden, 2001; Mendelsohn, 2002; Zwick et al, 2002). The gene discussed is EGFR; the disease is cancer.